Excellence in Research and Innovation for Humanity

ICTAD 2018 : 20th International Conference on Thrombophilic and Antiphospholipid Disorders

Cape Town, South Africa
November 15 - 16, 2018

Call for Papers

The ICTAD 2018 : 20th International Conference on Thrombophilic and Antiphospholipid Disorders is the premier interdisciplinary platform for the presentation of new advances and research results in the fields of Thrombophilic and Antiphospholipid Disorders. The conference will bring together leading academic scientists, researchers and scholars in the domain of interest from around the world. Topics of interest for submission include, but are not limited to:
  • Antiphospholipid Antibodies, Antiphospholipid Syndrome (APS), and Obstetric APS for Patients
  • Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies with New Generation Oral Anticoagulants, B-cell inhibition, Complement Inhibition, Hydroxychloroquine, Statins, Peptide Therapy, and others)
  • Association with Antiphospholipid Syndrome and Other Systemic Autoimmune Diseases (Systemic Lupus Erythematosis, Rheumatoid Arthritis)
  • Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests
  • Current Treatment strategies for Non-obstetric Antiphospholipid Syndrome
  • Current Treatment strategies for Obstetric Antiphospholipid Syndrome
  • Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome
  • Disease Measurement Criteria in Antiphospholipid Syndrome
  • Genetics of Antiphospholipid Antibodies/Syndrome
  • Impact of Antiphospholipid Syndrome in General Population with Thrombosis and Pregnancy Morbidity
  • Impact of Pediatric APS in Children with Thrombosis
  • Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity
  • Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis
  • Microangiopathic and Catastrophic Antiphospholipid Syndrome
  • Most Recent Strategies in the Treatment of Thrombosis in General Population
  • Origin of Antiphospholipid Antibodies
  • Strengths and Limitations of the Current Classification Criteria
  • Target Cells and Receptors that Interact with Antiphospholipid Antibodies
  • Thrombophilic and Antiphospholipid Disorders